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Background: The presence of increased B-cell tumor infiltrating lymphocytes (TILs) was seen in mouse prostate
cancer (PCa) but has not been fully documented in human PCa. We, therefore, investigated the density of
infiltrating B cells within human PCa utilizing a quantitative computational method.
Methods: Archived radical prostatectomy specimens from 53 patients with known clinical outcome and D’Amico
risk category were obtained and immunohistochemically (IHC) stained for the B cell marker, CD20. Slides were
reviewed by a genitourinary pathologist who manually delineated the tumoral regions of PCa. Slides were digitally
scanned and a computer algorithm quantified the area of CD20 stained B-cells as a measure of B cell density within
the outlined regions of prostate cancer (intra-tumoral region), versus extra-tumoral prostate tissue. Correlations were
analyzed between B-cell density and demographic and clinical variables, including D’Amico risk groups and disease
recurrence.
Results: For the entire cohort, the mean intra-tumoral B cell density was higher (3.22 SE = 0.29) than in the extra-tumoral
region of each prostatectomy section (2.24, SE = 0.19) (paired t test; P < 0.001). When analyzed according to D’Amico risk
group, the intra-tumoral B cell infiltration in low risk (0.0377 vs. 0.0246; p = 0.151) and intermediate risk (0.0260 vs. 0.0214;
p = 0.579) patient prostatectomy specimens did not show significantly more B-cells within the PCa tumor. However,
patient specimens from the high-risk group (0.0301 vs. 0.0197; p < 0.001) and from those who eventually had PCa
recurrence or progression (0.0343 vs. 0.0246; p = 0.019) did show significantly more intra-tumoral CD20+ B-cell staining.
Extent of B-cell infiltration in the prostatectomy specimens did not correlate with any other clinical parameters.
Conclusions: Our study shows that higher B-cell infiltration was present within the intra-tumoral PCa regions compared
to the extra-tumoral benign prostate tissue regions in prostatectomy sections. For this study we developed a new
method to measure B-cells using computer-assisted digitized image analysis. Accurate, consistent quantitation of B-cells in
prostatectomy specimens is essential for future clinical trials evaluating the effect of B cell ablating antibodies.
The interaction of B-cells and PCa may serve as the basis for new therapeutic targets.
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Understanding of the immune system’s role in modula-
tion of solid malignancies has increased significantly in
recent years. Both the innate and adaptive branches of
the host immune system have been shown to mount
responses against prostate tumor cells [1,2]. Immuno-
therapeutics represent a new paradigm in treating PCa
by augmenting the host immune system [1]. Current im-
munotherapeutics in use or under investigation include
tumor vaccines that enhance the function of antigen
presenting cells (APCs) and monoclonal antibody immu-
notherapeutics known as checkpoint modulators that are
now the target of several therapeutics in the clinic [3]. All
these drugs ultimately target T-cell mediated responses [3].
However, the role of B-cell immunity in PCa is not well
understood, and represents an opportunity for further in-
vestigation and therapeutic development.
Recently, CD20+ B-cell TILs were found to have prognos-
tic significance in melanoma, breast, non-small cell lung
cancer, and ovarian cancers [3-6]. However, the presence of
increased B-cell TILs has not been systematically investi-
gated in PCa [7-9]. Pre-clinical models have demonstrated
that B-cells play an important role in castrate-resistant PCa
(CRPC) [10-12]. Androgen ablation in murine models and
the consequent PCa cell death cause damage to the stromal
cell compartment of the tumor microenvironment, that
elicit leukocyte recruitment, including B cells, that promote
PCa recurrence [10,11]. B cell recruitment depends on the
chemokine, CXCL13, whose expression is induced in re-
sponse to androgen ablation [11]. Importantly, the tumor
infiltrating B cells produce lymphotoxin (LT), a heterotri-
meric cytokine that belongs to the TNF family, leading to
activation of IκB kinase α (IKKα) and STAT3 which pro-
mote survival and proliferation of androgen-deprived PCa
cells resulting in development of CRPC [11]. IKKα activa-
tion results in phosphorylation of E2F1 and enhanced tran-
scription of the BMI1 gene which encodes a component of
the polycomb ubiquitin ligase complex [11,12]. Elevated ex-
pression of BMI1 results in accumulation of ubiquitinated
histones in PCa nuclei [10-12]. These molecular events are
required for B cell-dependent, castrate-resistant regrowth
of the prostate cancer cells [11].
As a first step towards translation of the murine studies
to the clinic, we investigated the density of B-cells within
PCa tumor tissue from patients with differing risks of PCa
recurrence. The presence and location of B-cells within
prostate cancer tissue from patients who underwent pros-
tatectomy was investigated utilizing a reproducible and
quantitative computational method of identifying B-cells.
Methods
Selection of cases and patient population
After approval from the UCSD institutional review board
(IRB), 53 formalin-fixed, paraffin-embedded (FFPE) radicalprostatectomy specimens from separate patients were sub-
jected to CD20 immunohistochemical (IHC) analysis. The
patients were selected based on known clinical outcome ac-
cording to risk categories of low, intermediate and high-risk
groups based on the D’Amico risk classification [13], as well
as a group of patients with disease recurrence. Additional
clinical characteristics of each patient including age, race,
body mass index (BMI), co-morbidities, family history, pre-
operative PSA, Gleason score, and pathological data were
obtained.
Immunohistochemistry
Radical prostatectomy specimens were cut into 5 mm
axial sections, formalin-fixed and routinely processed for
paraffin embedding. Subsequently the embedded speci-
mens were cut into 5 μm sections and stained with
hematoxylin and eosin (H and E). Paraffin sections
were deparaffinzed, rehydrated, and blocked for endo-
genous peroxidases and endogenous biotin. Epitopes were
revealed using antigen retrieval in citrate buffer, pH 6.0
(DAKO catalog # S1700). Slides were incubated with
mouse anti-CD20 antibody (DAKO, catalog # MO755) in
blocking solution consisting of 1% BSA, PBS-Tween 20.
Bound anti-CD20 antibody was detected using the
Envision Horseradish peroxidase (HRP)-labeled anti-
mouse secondary antibody (DAKO catalog # K4000)
and 3-amino-9-ethylcarbazole (AEC) substrate chro-
magen (DAKO catalog # 3464) then counter-stained
with hematoxylin [14].
Data collection and image analysis
A board-certified genitourinary pathologist (A.S.) reviewed
IHC-stained slides, and the areas of tumor were manually
identified and marked on the slides (Figure 1a and b). All
slides were scanned using the Aperio ScanScope XT
system (Aperio®; Vista, CA). The Spectrum Analysis
algorithm package and ImageScope analysis software
were applied to quantify IHC staining. The raw image
data were in RGB format in which the colors of red,
blue, and green make up a 256-level scale. Colors
were represented as discrete variables, and each color
was assigned a numerical value between 0 and 255.
The color derived at each pixel was represented digit-
ally by its three separate values indicating the level of
red, green, and blue. The “color deconvolution” algo-
rithm (version 9, Aperio®, Vista, CA) was created to
quantitatively analyze the slides for the presence of
the AEC stain corresponding to CD20+ B-cells. This
algorithm identifies the AEC stained areas, based on
specific thresholds for the presence of red, green and
blue established for AEC. Areas of tissue folds, pen
marks, and air bubbles were identified and excluded
from our analysis as they disrupted the software
analysis.
Figure 1 Immunohistochemical staining of prostatectomy sections with anti-CD20 antibody. Paraffin-embedded, formalin fixed prostatec-
tomy sections were stained with anti-CD20 and counterstained with hematoxylin, The majority of CD20 immunostained B-cells are localized in im-
mune cell foci. Many in close proximity to prostate cancer cells as shown. Inset shows whole slide scan with blue-pen marked tumor regions in
each prostatectomy section.
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The primary outcome was the mean density of B-cells
within the area of tumor versus the B-cell density out-
side of the tumor area. B-cell density was recorded for
the entire specimen, within PCa tumor region (intra-tu-
moral), and outside tumor region (extra-tumoral) using
the following calculations:
AECpositivearea intra−tumoral region mm2ð Þ
Total Intra−Tumoral area mm2ð Þ and
AEC positiveareawithinprostate tissue mm2ð Þ
Total Extra−tumoral prostate area mm2ð Þ
Samples were analyzed based on the three D’Amico
Risk groups and in a population of patients who had
recurrence in a pilot analysis. B-cell density was skewed
to the right; therefore, the non-parametric Kruskal-
Wallace test was used to compare the overall B-cell
density in each D’Amico risk group or Gleason group
(<6, 7, and >7). Paired-t test was utilized to determine
the location of the B-cells within each prostatectomy
specimen and graphically displayed in a difference plot.
The statistics package SPSS v.21 (IBM, Chicago, IL, USA)
was used.
Results
The aim of this study was to determine the potential of
using B-cell infiltration as a prognostic marker of PCa
recurrence. CD20 IHC was performed on a cohort of
53 paraffin-embedded radical prostatectomy specimens
from D’Amico risk-stratified patients selected from theUCSD Urologic Oncology database. Demographics and
clinicopathological features for the cohort are displayed
in Tables 1 and 2. Diagnoses potentially related to in-
flammation such as hypertension, hypercholesterolemia,
and coronary artery disease remained relatively low in
the population. B-cell density was measured as the area
of CD20 positive B-cells (mm2) per analyzed area of
prostatectomy section (mm2). The analyzed areas were:
the total B-cell density of the entire area of the speci-
men, the intra-tumoral B-cell density within the outlined
PCa tumor area, and extra-tumoral B-cell density out-
side the tumor area. The primary outcome of this study
was to determine the location of highest B-cell density
in prostatectomy specimens.
The majority of anti-CD20 immunostained B-cells were
localized in immune cell foci, and many B-cells were
in close proximity to prostate cancer cells (Figure 1). Spe-
cificity of immunostaining was shown using the anti-
CD20 antibody stained specimen (Figure 2a) compared
to the isotype negative control antibody as shown in
(Figure 2c). Slides were digitally scanned and pixel staining
intensity was quantified using an AperioScope deconvolu-
tion algorithm (described below) in which staining intensity
pixels were represented as pseudo colors: high intensity as
red, intermediate intensity as orange and low intensity as
yellow (Figure 2b). Serial sections stained with isotype con-
trol antibody were used to set threshold of non-specific
background staining (Figure 2d). The area of tumor within
each slide was then outlined digitally using the Image-
Scope software (Figure 3). Within each area of tumor,
the total area (mm2) of AEC-positive cells was calcu-
lated using the color deconvolution algorithm as
Table 2 Operative and pathological details and outcomes
ALL (n = 53)
Median operative time (IQR), mins 189 (170–200)
Median estimated blood loss (IQR), mL 150 (100–200)
Median prostate weight (IQR), gm 44.7 (38–57.1)
Blood transfusions 1 (1.8%)
Lymph node dissection 37 (69.8%)
Complete nerve sparing 37 (69.8%)
Median hospital stay (IQR), days 1 (1–1)
Median lymph nodes retrieved (IQR) 17 (12–21)
Positive LN 5 (9.4%)
Median tumor size (IQR), cc 6.9 (2.6–13.7)
Positive margins 20 (41.5%)
Seminal vesicle involvement 6 (11.3%)
Extra capsular extension 15 (28.3%)
Perineural invasion 44 (83.0%)
Extensive prostatic intraepithelial neoplasia 5 (9.4%)






≤ 6 13 (24.5%)
7 16 (30.2%)
≥ 8 24 (45.3%)
Table 1 Demographic and clinical characteristics
ALL (n = 53)








Coronary artery disease 4 (7.5%)
5 Alpha-Reductase (Proscar/Avodart) 8 (15.1%)
Primary relative with prostate Ca 17 (32.1%)






≤ 6 20 (37.7%)
7 17 (32.1%)
≥ 8 16 (30.2%)
D'Amico risk group
Low risk 10 (16.7%)
Intermediate risk 9 (15.0%)
High risk 15 (25%)
Recurrence 26 (43.3%)
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repeated for the area of AEC-positive cells within the
non-tumor areas of the specimen.
The primary hypothesis was that there would be more
B-cells within the tumor than surrounding non-tumor
areas. Using paired statistical analysis to account for
individual variation, the mean intra-tumoral B-cell density
was higher (3.22 SE = 0.29) than outside the tumor region
(extra-tumoral) (2.24, SE = 0.19) (paired t-test; P < 0.001) in
the whole cohort.
Correlations between B-cell density and demographic
variables were investigated, with attention to inflamma-
tory mediated disease such as hypertension, hypercholes-
terolemia, and coronary artery disease. No correlations
were noted between overall B-cell density or intra-
tumoral B cell density compared to age, body mass
index, race, hypertension, hypercholesterolemia, diabetes,
family history of prostate cancer, coronary artery disease or
history of 5-alpha reductase inhibitors (all p > 0.05).
Samples were analyzed based on the three D’Amico
Risk groups and in a population of patients who hadrecurrence in a pilot analysis. B-cell density was skewed to
the right; therefore, the non-parametric Kruskal-Wallace
test was used to compare the overall B-cell density in each
D’Amico risk group or Gleason group (<6, 7, and >7).
Comparing the B-cell density within the tumor and
outside the tumor in D’Amico low risk (0.0377 vs. 0.0246;
p = 0.151) and intermediate risk (0.0260 vs. 0.0214;
p = 0.579) did not show significant differences (Figure 4).
However, the D’Amico high-risk group and recurrence
group did show more intra-tumoral CD20+ B cell staining
compared to extra-tumoral (0.0301 vs. 0.0197; p < 0.001)
and (0.0343 vs. 0.0246; p = 0.019), respectively (Figure 4).
In order to take into account the variation between pa-
tients in their overall B cell density in the prostate, the B
cell densities for individual patients were determined
based on their location in the prostatectomy specimens,
that is, intra-tumoral compared to extra-tumoral re-
gions. The B-cell densities (mm2) were measured after
CD20 staining of radical prostatectomy and computer
generated values of area of staining was divided by area
analyzed. This density was calculated within the tumor
and outside the tumor and the difference was compared
Figure 2 Computer-supported digital quantification of analysis CD20 immunohistochemical staining of prostatectomy sections. a
prostatectomy section anti-CD20 stained slide, b serial section stained with isotype negative control antibody (mouse IgG). c Imagescope decon-
volution algorithm is applied, color intensity is converted to representation as image pixels with high intensity (brown), intermediate (orange) and
low (yellow) staining intensity. d represents the isotype negative control antibody (mouse IgG) in b after applying the deconvolution algorithm.
Figure 3 Tumor region selection and digital quantification. A genitourinary pathologist manually marked the tumor regions in each section
on each slide using blue permanent pen marks (a and b). Using ImageScope software the tumor regions were digitally outlined as shown with
the solid green lines. The deconvolution algorithm was applied to the outlined tumor region as shown in c and d. The intra-tumoral B cell density
was quantified as the area of CD20 stained (mm2) of AEC-positive cells (c and d).
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Figure 4 Intra-tumoral B-cell density compared to and extra-tumoral B cell density in each D'Amico risk group. Box plots representing
the B-cell density inside the delineated tumor region (intra-tumoral) and outside the tumor regions (extra-tumoral) in radical prostatectomy
speciments. B cell density was defined as: the area of CD20 positive staining (mm2)/ total area analyzed ie. intra-or extra-tumoral prostatectomy
tissue region in each section. The B cell densities in the intra-tumoral regions were compared to the extra-tumoral regions in each of the D'Amico
risk groups: low (n = 10), intermediate (n = 9), and high (n = 15) and in the group of patients with known prostate cancer recurrence (n = 26). The
median B cell density is shown as the horizontal line in each box plot. Asterisk over recurrence group indicates outlier.
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represents an individual patient’s intra-tumoral B-cell
density minus their extra-tumoral B-cell density to
display the magnitude of difference in B-cell location per
patient. For the entire cohort, the mean intra-tumoral B
cell density was higher (3.22 SE = 0.29) than in the extra-
tumoral region of each prostatectomy section (2.24,
SE = 0.19) (paired t test; P < 0.001).
Discussion
The results of our study show that intra-tumoral B-cells
were present in higher numbers in comparison to the
extra-tumoral regions of adjacent non-malignant tissue
in each of the radical prostatectomy specimens. To reduce
sampling error and intra- and inter-observer variability,
B-cells were quantitated using computer supported image
analysis.
Tumor infiltrating lymphocytes (TILs), particularly
CD8+ T cells, have been shown to have strong positive
prognostic relevance in multiple other solid tumors
[15-17]. However, the role of B-cell immunity in PCa is
not well understood, and represents an opportunity for
study and potential therapy. The majority of studies have
focused on CD8+ T cells, which have been recognized as
the lymphocytes with the strongest anti-tumor activity[15-17]. Previously, B-cells have been reported as less
abundant in prostate tissue than T-cells or macrophages
[15-18]. However, analyses of B-cell density have varied,
depending on tissue type, histological methods, and
technique used. Hussein et al. reviewed 50 transurethral
resection of prostate specimens with high-grade PCa,
and found that the number of manually-counted CD20+
cells was significantly higher in adenocarcinoma than in
normal prostate [19]. Fujii et al. reviewed 100 radical pros-
tatectomy specimens by manually estimating lymphocyte
percentages and showed opposing results, as the frequency
on B-cells in benign tissue was actually higher in benign
tissue than in adenocarcinoma [8]. Other investigators used
tissue microarrays (TMA) to quantify B-cells [18-21]. A
limitation of TMAs in quantifying prostatic B-cells is sam-
pling error, as prostate adenocarcinomas are often hetero-
geneous and larger than the tissue cylinder used in TMA.
B-cells in particular are scant and variable, often forming
into sporadic clusters that can increase sampling error
when using such methods [20-23]. Our computer sup-
ported analysis of the whole prostatectomy section as well
as specific regions within each section allowed the quantifi-
cation of large amounts of tissue to confirm a statistically
significant higher number of B-cells in the tumor regions
of each tissue section. While TMA analyses sample an
Figure 5 Individual patients B-cell location in prostatectomy specimens. The B-cell densities (mm2) were measured after CD20 staining of
radical prostatectomy and computer generated values of area of staining was divided by area analyzed. This density was calculated within the
tumor and outside the tumor and the difference was compared using the paired t-test. Each dot represents an individual patient’s intra-tumoral
B-cell density minus their extra-tumoral B-cell density to display the magnitude of difference in B-cell location per patient.
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was approximately 300 mm2 per sample. This is a novel
implementation of the computer image supported analysis
in prostate tissue.
To overcome the limitations of sampling error and
intra- and inter-observer variability in quantifying lym-
phocytes, computer-supported image analysis was used
to quantify the area of the CD20+ B-cells over the entir-
ety of the radical prostatectomy specimens. Protein
quantification by IHC remains semi-quantitative and is
subject to variability between interpreters with the use
of manual (‘eyeballing’) scoring systems [24]. Digital
quantification of IHC staining was first described 20
years ago, but until recently its adoption has been lim-
ited due to insufficient technology and lack of validated
standards in image acquisition and analysis [25-27].
CD20+ staining is specific to B-cells and the color of the
AEC stain is distinct from any background staining, so
color analysis rather than morphological analysis is ac-
curate. The images are saved in RGB format with each
color represented as a variable on the 256-color scale,
thus we are able to establish discrete color thresholds
that will allow the software to identify the specific color
of the AEC stain. Given the range of possible color
thresholds, this allows for analysis of a continuous
spectrum of results rather than a pre-defined visual
scoring system (e.g. “present vs absent” or “0, 1, 2, 3”).
This allows for the more flexible statistical evaluation
such as multi-parametric calculations, which may revealassociations not present in manual analyses [27]. Given
the reliability of this technique in our experience, we an-
ticipate future use of digital image assessment in prostate
B-cell research and, perhaps, in the clinical setting.
Analysis of B cell density in these prostatectomy speci-
mens failed to demonstrate a correlation between the
intra-tumoral density of B-cells and the separate clinical
and pathological parameters from our patient cohort.
This is consistent with prior series that did not find
associations between B-cell TILs and patient clinical fea-
tures [18,21]. Prior studies with TMA analyses of radical
prostatectomy specimens showed that B-cells were not
associated with PSA-free survival, clinical stage, lymph
node status, Gleason score or PSA [18,21]. The prognos-
tic implications of T-cells in PCa tissue also remains
controversial, with conflicting evidence linking high
T-cell counts to both negative and positive prognosis
[18,21,28-30]. In other better-studied solid malignancies
such as colorectal and ovarian cancer, higher intra-tumoral
T-cell counts have been associated with better clinical out-
comes, indicating the biological impact of the immune
system on tumor development and progression [21].
Immunotherapies for PCa treatment have targeted
T-cell pathways. Sipuleucel-T (PROVENGE®; Dendreon,
Seattle, WA) is a tumor vaccine that enhances the func-
tion of antigen presenting cells and T-cells, and is FDA
approved for asymptomatic or minimally symptomatic
CRPC [31]. Ipilimumab (YERVOY™; Bristol-Myers Squibb,
Princeton, NJ) is a monoclonal antibody against cytotoxic
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checkpoint regulator [3,32]. Immune checkpoint blockade
“takes the brakes off the immune system” and improves
anti-tumor responses. Occupancy of CTLA-4 dampens
T-cell response against PCa [32]. Ipilimumab is cur-
rently in two Phase III clinical trials in patients with
metastatic castrate resistant prostate cancer (mCRPC):
http://1.usa.gov/ZKqSlg and http://1.usa.gov/146x4H
v#sthash. eS72VER7.dpuf.
Monoclonal antibodies against another checkpoint
modulator, PD-1, such as nivolumab (Bristol-Myers-
Squibb, BMS-936558), are also showing preliminary effi-
cacy in clinical trials for a number of cancers, though no
objective responses have been observed yet in Phase 1
trials in CRPC patients [33]. PD1 is thought to regulate
T cell activation at a later stage than CTLA4 and is
expressed on a wider range of immune cells including
activated T cells in the periphery, regulatory T cells
known as Tregs, activated B cells and NK cells [3,32]. Its
ligands PD-L1 and PD-L2 are expressed on immune
cells and non-immune cells including on some tumors.
Inhibition of PD1 signaling by anti-PD-L1 antibody ther-
apeutics are currently in clinical trials for a range of
cancers including prostate cancer [3,32,33].
Humoral immunity is of particular interest in PCa as
chronic inflammation appears to play a role in tumori-
genesis and metastatic progression, with emerging litera-
ture supporting a role for B-cell derived cytokines in
PCa progression [16,30]. After androgen ablation, B cell
infiltration into prostate tumor results in increased pro-
duction of LT and activation of IKKα and STAT3 to pro-
mote the emergence of CRPC [11]. Our analysis of B
cells in prostate tumors in this study lays the ground-
work for future clinical trials in which we plan to use
this method to quantify B cells along with other patho-
logic data or staining of additional markers such as
CXCL13, IKKα and BMI1 that were identified in the
murine preclinical studies into more quantitative ana-
lysis in patients [11,12]. We used this study of B-cell
quantitation as a recent example for an upcoming clin-
ical trial which we powered by using the paired T-test
with post-operative prostatectomy specimens in treated
and untreated patients using this technique with a sam-
ple size of twenty in each group.
The results must be viewed within the limitations of
the study and analysis of additional patients is necessary
to verify the results. The study did not show any associ-
ation between the number of B-cells and patient clinical
parameters, and the study may be underpowered to de-
tect differences between the risk groups, especially given
the low numbers of CD20+ cells in each specimen. How-
ever, the primary hypothesis that B-cells were higher in
malignant tissue (intra-tumoral) versus benign tissue
(extra-tumoral) was supported by the results.Conclusions
The findings of this study have implications for immuno-
therapy to treat prostate cancer. The first step in recogniz-
ing the B-cell pathway as a potential target in prostate
cancer is to consistently document the presence of CD20+
cells in malignant tissue, which we have done in a reprodu-
cible and quantitative computational method.
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